Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Aliskiren and Amlodipine in Essential Hypertension
NCT00739973Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (9 arms), sponsored by Novartis. Primary endpoint: Mean Sitting Diastolic Blood Pressure at 8 weeks. Started Sep 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00739973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739973.